

# Daniel Olive

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7802969/publications.pdf>

Version: 2024-02-01

95  
papers

7,409  
citations

76326

40  
h-index

58581

82  
g-index

105  
all docs

105  
docs citations

105  
times ranked

10555  
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-1 Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer. <i>Cancer Research</i> , 2013, 73, 128-138.	0.9	554
2	Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. <i>Journal of Clinical Investigation</i> , 2011, 121, 3609-3622.	8.2	524
3	Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human T-cell subset. <i>Blood</i> , 2012, 120, 2269-2279.	1.4	443
4	Defective expression and function of natural killer cell triggering receptors in patients with acute myeloid leukemia. <i>Blood</i> , 2002, 99, 3661-3667.	1.4	434
5	Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 335-346.e3.	2.9	379
6	Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCR dull phenotype induction. <i>Blood</i> , 2007, 109, 323-330.	1.4	321
7	BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. <i>Journal of Clinical Investigation</i> , 2010, 120, 157-167.	8.2	252
8	A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. <i>Blood</i> , 2012, 120, 4317-4323.	1.4	247
9	Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies. <i>Cancer Research</i> , 2015, 75, 2928-2936.	0.9	193
10	ICOS-Ligand Expression on Plasmacytoid Dendritic Cells Supports Breast Cancer Progression by Promoting the Accumulation of Immunosuppressive CD4+ T Cells. <i>Cancer Research</i> , 2012, 72, 6130-6141.	0.9	184
11	Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer. <i>Oncotarget</i> , 2015, 6, 14360-14373.	1.8	164
12	Reciprocal Expression of the TNF Family Receptor Herpes Virus Entry Mediator and Its Ligand LIGHT on Activated T Cells: LIGHT Down-Regulates Its Own Receptor. <i>Journal of Immunology</i> , 2000, 165, 4397-4404.	0.8	161
13	Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity. <i>Cancer Research</i> , 2016, 76, 2153-2165.	0.9	154
14	The Molecular Basis for Modulation of Human T <sub>H</sub> 2 T Cell Responses by CD277/Butyrophilin-3 (BTN3A)-specific Antibodies. <i>Journal of Biological Chemistry</i> , 2012, 287, 32780-32790.	3.4	139
15	RhoB Mediates Phosphoantigen Recognition by T <sub>H</sub> 2 Cell Receptor. <i>Cell Reports</i> , 2016, 15, 1973-1985.	6.4	112
16	Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer. <i>Trends in Immunology</i> , 2010, 31, 391-397.	6.8	107
17	Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2018, 9, 1044.	4.8	107
18	Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma. <i>Oncolmmunology</i> , 2019, 8, e1561120.	4.6	92

#	ARTICLE	IF	CITATIONS
19	PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance. <i>Onc Immunology</i> , 2016, 5, e1064578.	4.6	91
20	Frontline: Characterization of BT3 molecules belonging to the B7 family expressed on immune cells. <i>European Journal of Immunology</i> , 2004, 34, 2089-2099.	2.9	90
21	The co-receptor BTLA negatively regulates human V $\beta$ 9V $\alpha$ 2 T-cell proliferation: a potential way of immune escape for lymphoma cells. <i>Blood</i> , 2013, 122, 922-931.	1.4	87
22	The butyrophilin (BTN) gene family: from milk fat to the regulation of the immune response. <i>Immunogenetics</i> , 2012, 64, 781-794.	2.4	85
23	High Expression of the Inhibitory Receptor BTLA in T-Follicular Helper Cells and in B-Cell Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia. <i>American Journal of Clinical Pathology</i> , 2009, 132, 589-596.	0.7	81
24	Endometrial Tumor Microenvironment Alters Human NK Cell Recruitment, and Resident NK Cell Phenotype and Function. <i>Frontiers in Immunology</i> , 2019, 10, 877.	4.8	81
25	Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity. <i>Frontiers in Immunology</i> , 2014, 5, 122.	4.8	75
26	V $\beta$ 9V $\alpha$ 2 TCR $\epsilon$ activation by phosphorylated antigens requires butyrophilin 3 A1 (BTN3A1) and additional genes on human chromosome 6. <i>European Journal of Immunology</i> , 2014, 44, 2571-2576.	2.9	71
27	New Insights Into the Regulation of V $\beta$ 1 T Cells by BTN3A and Other BTN/BTNL in Tumor Immunity. <i>Frontiers in Immunology</i> , 2018, 9, 1601.	4.8	68
28	Follicular B Lymphomas Generate Regulatory T Cells via the ICOS/ICOSL Pathway and Are Susceptible to Treatment by Anti-ICOS/ICOSL Therapy. <i>Cancer Research</i> , 2016, 76, 4648-4660.	0.9	65
29	Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 343-351.	3.4	64
30	The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy. <i>Current Opinion in Pharmacology</i> , 2012, 12, 478-485.	3.5	61
31	Differential role for CD277 as a co-regulator of the immune signal in T and NK cells. <i>European Journal of Immunology</i> , 2011, 41, 3443-3454.	2.9	59
32	Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity. <i>Immunology Letters</i> , 2013, 151, 71-75.	2.5	59
33	HCV glycoprotein E2 is a novel BDCA-2 ligand and acts as an inhibitor of IFN production by plasmacytoid dendritic cells. <i>Blood</i> , 2012, 120, 4544-4551.	1.4	58
34	Two alternate strategies for innate immunity to Epstein-Barr virus: One using NK cells and the other NK cells and V $\beta$ 1 T cells. <i>Journal of Experimental Medicine</i> , 2017, 214, 1827-1841.	8.5	57
35	Vitamin D Controls Tumor Growth and CD8+ T Cell Infiltration in Breast Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1307.	4.8	56
36	Reconstitution of Natural Killer Cells in HLA-Matched HSCT after Reduced-Intensity Conditioning: Impact on Clinical Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 429-439.	2.0	55

#	ARTICLE	IF	CITATIONS
37	Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. <i>Oncolmmunology</i> , 2020, 9, 1832348.	4.6	55
38	Î³Î² T cell diversity and the receptor interface with tumor cells. <i>Journal of Clinical Investigation</i> , 2020, 130, 4637-4651.	8.2	49
39	Development of ICTO1, a first-in-class, anti-BTN3A antibody for activating VÎ³9VÎ²2 T cell-mediated antitumor immune response. <i>Science Translational Medicine</i> , 2021, 13, eabj0835.	12.4	49
40	Butyrophilin 3A (BTN3A, CD277)-specific antibody 20.1 differentially activates VÎ³9VÎ²2 TCR clonotypes and interferes with phosphoantigen activation. <i>European Journal of Immunology</i> , 2017, 47, 982-992.	2.9	47
41	Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia. <i>Frontiers in Immunology</i> , 2017, 8, 573.	4.8	47
42	BTN3A is a prognosis marker and a promising target for VÎ³9VÎ²2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC). <i>Oncolmmunology</i> , 2018, 7, e1372080.	4.6	47
43	BTN3A molecules considerably improve VÎ³9VÎ²2 T cells-based immunotherapy in acute myeloid leukemia. <i>Oncolmmunology</i> , 2016, 5, e1146843.	4.6	46
44	Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing. <i>Nature Communications</i> , 2022, 13, .	12.8	45
45	BTN2A1, an immune checkpoint targeting VÎ³9VÎ²2 T cell cytotoxicity against malignant cells. <i>Cell Reports</i> , 2021, 36, 109359.	6.4	44
46	NKG2C <sup>+</sup> memory-like NK cells contribute to the control of HIV viremia during primary infection: Optprimâ€œANRS 147. <i>Clinical and Translational Immunology</i> , 2017, 6, e150.	3.8	42
47	Hepatitis C Virus Is a Weak Inducer of Interferon Alpha in Plasmacytoid Dendritic Cells in Comparison with Influenza and Human Herpesvirus Type-1. <i>PLoS ONE</i> , 2009, 4, e4319.	2.5	40
48	Butyrophilin 3A/CD277-Dependent Activation of Human Î³Î² T Cells: Accessory Cell Capacity of Distinct Leukocyte Populations. <i>Journal of Immunology</i> , 2016, 197, 3059-3068.	0.8	40
49	NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML. <i>Oncolmmunology</i> , 2017, 6, e1307491.	4.6	37
50	The Juxtamembrane Domain of Butyrophilin BTN3A1 Controls Phosphoantigen-Mediated Activation of Human VÎ³9VÎ²2 T Cells. <i>Journal of Immunology</i> , 2017, 198, 4228-4234.	0.8	36
51	Cell-Laden Hydrogel as a Clinical-Relevant 3D Model for Analyzing Neuroblastoma Growth, Immunophenotype, and Susceptibility to Therapies. <i>Frontiers in Immunology</i> , 2019, 10, 1876.	4.8	35
52	HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma. <i>Oncolmmunology</i> , 2019, 8, e1665976.	4.6	35
53	Dual Role of the Tyrosine Kinase Syk in Regulation of Toll-Like Receptor Signaling in Plasmacytoid Dendritic Cells. <i>PLoS ONE</i> , 2016, 11, e0156063.	2.5	35
54	Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma. <i>Oncolmmunology</i> , 2019, 8, 1615818.	4.6	34

#	ARTICLE	IF	CITATIONS
55	NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 49548-49563.	1.8	34
56	Phosphoantigens and butyrophilin 3A1 induce similar intracellular activation signaling in human TCRV $\beta$ 9+ $\beta$ 17 T lymphocytes. <i>Immunology Letters</i> , 2014, 161, 133-137.	2.5	33
57	Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors. <i>Frontiers in Immunology</i> , 2018, 9, 797.	4.8	33
58	A Mature NK Profile at the Time of HIV Primary Infection Is Associated with an Early Response to cART. <i>Frontiers in Immunology</i> , 2017, 8, 54.	4.8	30
59	Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology. <i>Biomedicines</i> , 2021, 9, 632.	3.2	30
60	PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 150-161.	3.4	29
61	High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	29
62	Hepatitis C Virus Fails To Activate NF- $\kappa$ B Signaling in Plasmacytoid Dendritic Cells. <i>Journal of Virology</i> , 2012, 86, 1090-1096.	3.4	28
63	Targeting the Human T-Cell Inducible Costimulator Molecule with a Monoclonal Antibody Prevents Graft-vs-Host Disease and Preserves Graft vs Leukemia in a Xenograft Murine Model. <i>Frontiers in Immunology</i> , 2017, 8, 756.	4.8	28
64	Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses. <i>PLoS ONE</i> , 2017, 12, e0179201.	2.5	28
65	Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells. <i>Frontiers in Immunology</i> , 2016, 7, 94.	4.8	26
66	The MEK1/2-ERK Pathway Inhibits Type I IFN Production in Plasmacytoid Dendritic Cells. <i>Frontiers in Immunology</i> , 2018, 9, 364.	4.8	26
67	Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients. <i>Human Pathology</i> , 2017, 64, 128-136.	2.0	25
68	Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities. <i>Frontiers in Immunology</i> , 2018, 9, 977.	4.8	25
69	Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy. <i>Journal of Leukocyte Biology</i> , 2021, 109, 1071-1088.	3.3	25
70	Increased NK Cell Maturation in Patients with Acute Myeloid Leukemia. <i>Frontiers in Immunology</i> , 2015, 6, 564.	4.8	24
71	Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis. <i>Human Pathology</i> , 2014, 45, 2085-2093.	2.0	23
72	Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity. , 2022, 10, e004244.		23

#	ARTICLE	IF	CITATIONS
73	The SH3 domain of Tec kinase is essential for its targeting to activated CD28 costimulatory molecule. <i>European Journal of Immunology</i> , 2004, 34, 1972-1980.	2.9	22
74	Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade. <i>Blood Advances</i> , 2021, 5, 1816-1829.	5.2	22
75	Evolutionary and polymorphism analyses reveal the central role of BTN3A2 in the concerted evolution of the BTN3 gene family. <i>Immunogenetics</i> , 2017, 69, 379-390.	2.4	21
76	Blockade of HVEM for Prostate Cancer Immunotherapy in Humanized Mice. <i>Cancers</i> , 2021, 13, 3009.	3.7	20
77	NK cells and multiple myeloma-associated endothelial cells: molecular interactions and influence of IL-27. <i>Oncotarget</i> , 2017, 8, 35088-35102.	1.8	20
78	ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells. <i>Blood Advances</i> , 2020, 4, 5203-5214.	5.2	18
79	Natural Killer Cell-triggering Receptors in Patients with Acute Leukaemia. <i>Leukemia and Lymphoma</i> , 2003, 44, 1683-1689.	1.3	17
80	Ligation of the BT3 molecules, members of the B7 family, enhance the proinflammatory responses of human monocytes and monocyte-derived dendritic cells. <i>Molecular Immunology</i> , 2010, 48, 109-118.	2.2	17
81	Enediynes bearing polyfluoroaryl sulfoxide as new antiproliferative agents with dual targeting of microtubules and DNA. <i>European Journal of Medicinal Chemistry</i> , 2018, 148, 306-313.	5.5	12
82	Î³Î² T Cells in Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1273, 91-104.	1.6	12
83	Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor. <i>Cancers</i> , 2021, 13, 2673.	3.7	12
84	Photoactivated cyclization of aryl-containing enediynes coated gold nanoparticles: Enhancement of the DNA cleavage ability of enediynes. <i>Colloids and Surfaces B: Biointerfaces</i> , 2013, 112, 513-520.	5.0	11
85	Identification of an Immature Subset of PMN-MDSC Correlated to Response to Checkpoint Inhibitor Therapy in Patients with Metastatic Melanoma. <i>Cancers</i> , 2021, 13, 1362.	3.7	11
86	Role of VÎ²9Î²2 T lymphocytes in infectious diseases. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	11
87	Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 670827.	4.8	10
88	An X-ray Vision for Phosphoantigen Recognition. <i>Immunity</i> , 2019, 50, 1026-1028.	14.3	7
89	Local Ablative Therapy Associated with Immunotherapy in Locally Advanced Pancreatic Cancer: A Solution to Overcome the Double Trouble?â€”A Comprehensive Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 1948.	2.4	7
90	Quantification of Immune Variables from Liquid Biopsy in Breast Cancer Patients Links VÎ²2+ Î³Î² T Cell Alterations with Lymph Node Invasion. <i>Cancers</i> , 2021, 13, 441.	3.7	6

#	ARTICLE	IF	CITATIONS
91	Chronic IL-15 Stimulation and Impaired mTOR Signaling and Metabolism in Natural Killer Cells During Acute Myeloid Leukemia. <i>Frontiers in Immunology</i> , 2021, 12, 730970.	4.8	6
92	Phosphoantigen-Stimulated $\gamma\delta$ T Cells Suppress Natural Killer Cell Responses to Missing-Self. <i>Cancer Immunology Research</i> , 2022, 10, 558-570.	3.4	4
93	BTN3A Targeting $\gamma\delta$ T Cells Antimicrobial Activity Against <i>Coxiella burnetii</i> -Infected Cells. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
94	CD47-SIRP $\alpha$ Controls ADCC Killing of Primary T Cells by PMN Through a Combination of Trogocytosis and NADPH Oxidase Activation. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	3
95	A Tribute to Alessandro Moretta (1953-2018). <i>Living Without Alessandro</i> . <i>Frontiers in Immunology</i> , 2018, 9, .	4.8	1